Israel Englander Athersys, Inc Transaction History

Millennium Management LLC

  • $199 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$0.18 - $0.86 $330,614 - $1.58 Million
1,836,746 Added 381.77%
2,317,856 $603,000
Q1 2022

May 16, 2022
BUY
$0.6 - $1.06 $130,417 - $230,404
217,363 Added 82.41%
481,110 $291,000
Q4 2021

Feb 14, 2022
SELL
$0.85 - $1.4 $281,457 - $463,577
-331,127 Reduced 55.66%
263,747 $238,000
Q3 2021

Nov 15, 2021
SELL
$1.33 - $1.77 $542,576 - $722,075
-407,952 Reduced 40.68%
594,874 $791,000
Q2 2021

Aug 16, 2021
BUY
$1.41 - $1.94 $1.41 Million - $1.95 Million
1,002,826 New
1,002,826 $1.44 Million
Q1 2021

May 17, 2021
SELL
$1.61 - $2.77 $139,841 - $240,596
-86,858 Closed
0 $0
Q4 2020

Feb 16, 2021
SELL
$1.55 - $2.24 $881,384 - $1.27 Million
-568,635 Reduced 86.75%
86,858 $152,000
Q3 2020

Nov 16, 2020
SELL
$1.91 - $3.08 $3.47 Million - $5.59 Million
-1,814,215 Reduced 73.46%
655,493 $1.28 Million
Q2 2020

Aug 14, 2020
BUY
$1.97 - $3.98 $4.83 Million - $9.76 Million
2,451,742 Added 13646.57%
2,469,708 $6.82 Million
Q1 2020

May 14, 2020
BUY
$1.17 - $3.0 $21,020 - $53,898
17,966 New
17,966 $54,000
Q4 2018

Feb 14, 2019
SELL
$1.41 - $2.16 $356,013 - $545,382
-252,492 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$1.86 - $2.18 $381,625 - $447,281
-205,175 Reduced 44.83%
252,492 $530,000
Q2 2018

Aug 14, 2018
BUY
$1.76 - $2.79 $636,829 - $1.01 Million
361,835 Added 377.57%
457,667 $902,000
Q1 2018

May 15, 2018
SELL
$1.34 - $2.03 $27,829 - $42,159
-20,768 Reduced 17.81%
95,832 $175,000
Q4 2017

Feb 14, 2018
BUY
$1.65 - $2.45 $18,240 - $27,084
11,055 Added 10.47%
116,600 $211,000
Q3 2017

Nov 14, 2017
BUY
$1.5 - $2.55 $158,317 - $269,139
105,545
105,545 $217,000

About ATHERSYS, INC

ATHX Quotes by TradingView
  • Ticker ATHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 305,110,016
  • Market Cap $3.05M
  • Description
  • Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...
More about ATHX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email